NHS set to pilot GRAIL’s wide-ranging cancer blood test – PMLiVE

The UK’s National Health Service (NHS) has signed a deal with healthcare company GRAIL to pilot its novel cancer blood test in 165,000 patients.
The Galleri blood test will be offered to 165,000 patients by NHS England in a new programme aimed at detecting early stage cancers.
The blood test identifies signs of a range of cancer types by searching for small fragments of DNA and RNA from tumours in the bloodstream to determine the presence of cancer.
The NHS will identify programme participants…

Click here to view the original article.